Results

Eli Lilly ushers up-and-coming GIP/GLP-1 drug into PhIII as Novo Nordisk rival wows with impressive results

With Novo Nordisk’s GLP-1 drug Ozempic (semaglutide) on its tail, Eli Lilly has rounded up some mid-stage data to show it has the right candidate to follow on Trulicity’s blockbuster success in the competitive diabetes market.

Investigators report that LY3298176, a dual GIP and GLP-1 receptor agonist, outperformed both placebo and Trulicity (dulaglutide) in terms of blood sugar reduction and weight loss for patints with type 2 diabetes. And while cross-trial comparisons always warrant caution, the drug appears to offer a sizable additional effect over GLP monotherapies.

Like GLP-1, GIP is an incretin hormone tied to insulin secretion.

“This drug is setting up to be perhaps the most critical part of LLY’s diabetes strategy going fwd … especially in the face of Novo’s new launches,” Evercore ISI analyst Umer Raffat writes in a note.

Investors were paying close attention. Lilly’s stock $LLY shot up 4%, a big deal for big-cap company, while Novo’s shares $NVO slid 7%.

On the primary efficacy measure — change in HbA1c from baseline to 26 weeks — 90% of those who received the 10 mg dose of LY3298176 achieved the recommended HbA1c target of 7% of less; the 5 mg group record 69.1% and the 15 mg group, 77.4%. Meanwhile, the single dulaglutide and placebo arms had 52% and 12% of patients hitting that target.

Of note, the 15 mg group actually saw a higher percentage (30%) of patients achieving the most impressive reduction, which is HbA1c levels of less than 5.7% — what you’d expect to see in non-diabetics. Among those on the 10 mg dose, 18% got to that point.

But where LY3298176 really stood out was in the weight loss numbers: -4.8 kg (5 mg), -8.7 kg (10 mg) and -11.3 kg (15 mg) while patients on dulaglutide shed an average of -2.7 kg. That translates to more than a third of drug arm patients losing 10% or more of their baseline body weight.

Source: Umer Raffat

Researchers are also happy with the safety profile, which they say is “similar to the GLP-1 RA class” with the most commonly reported side effects being nausea, diarrhea and vomiting.

“We set a high bar for this Phase II study, and the results exceeded our expectations,” said Jeff Emmick, vice president of product development, Lilly Diabetes. “We’re excited to continue studying GIP/GLP-1 RA and hope to add it to our wide range of therapies for people with diabetes.”

It’s now time to move into a larger Phase III trial dubbed SURPASS, which Lilly plans to initiate by early 2019 and complete in late 2021.

If the data trends hold up — as Raffat is bullish it would — he sees the drug taking a key position in a bifurcating GLP-1 market:

  • oral sema will take lots of share from short-acting GLP-1s (where Novo is already pulling spend from Victoza) as well from orals
  • perhaps there will remain a long-acting niche … with Novo’s Ozempic and LLY’s Trulicity … LLY will likely shift the spend away from Trulicity and over to this GIP/GLP.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,500+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->